Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapy

Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapy

Abstract Immune-mediated protection generated to COVID-19 mRNA vaccines is associated with anti-Spike (S) protein neutralizing antibodies. However, humoral immunity is compromised in B cell depleting (BCD) therapies, used to treat autoimmune diseases such as Multiple Sclerosis (MS). To study the eff...

Full description

Saved in:
Bibliographic Details
Main Authors: Julia Davis-Porada, Ceren Tozlu, Claudia Aiello, Sokratis A. Apostolidis, Amit Bar-Or, Riley Bove, Diego A. Espinoza, Sugeidy Ferreira Brito, Dina Jacobs, Mihir Kakara, Kaho Onomichi, Adelle Ricci, Joseph J. Sabatino, Elizabeth Walker, E. John Wherry, Lili Zhang, Wen Zhu, Zongqi Xia, Philip De Jager, Sarah Flanagan Wesley, Rebecca Straus Farber, Donna L. Farber
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-025-01151-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41541-025-01151-8

Similar Items